Bevacizumab for advanced breast cancer

被引：20

作者：

Traina, Tiffany A.

Rugo, Hope S.

Dickler, Maura

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Canc Med Serv, New York, NY 10021 USA

[2] Univ Calif San Francisco, Ctr Comprehens Canc, Breast Oncol Clin Trials Program, San Francisco, CA 94143 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2007年 / 21卷 / 02期

关键词：

D O I：

10.1016/j.hoc.2007.03.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumor angiogenesis is essential for the growth and metastasis of solid tumors. In breast cancer, increased levels of vascular endothelial growth factor (VEGF) have been associated with poor prognosis in lymph nodepositive and lymph node-negative patients. In addition to its prognostic significance, VEGF is now a validated target in the treatment of breast cancer. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors. In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer.

引用

页码：303 / +

页数：18

共 67 条

[11]

DADAMO D, 2005, J CLIN ONCOL

[12]

Epstein M, 2002, BREAST CANCER RES TR, V76, pS143

[13] Role of vascular endothelial growth factor in the regulation of angiogenesis [J].